TN2009000357A1 - ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5¬(2,4-DIHYDROXY-5- ISOPROPYL-PHENYL)- 4- (4-MORPHOLIN -4¬YLMETHYL-PHENYL) - ISOXAZOLE-3-CARBOXYLlC ACID ETHYLAMIDE AND FORMULATIONS COMPRISING THESE FORMS - Google Patents
ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5¬(2,4-DIHYDROXY-5- ISOPROPYL-PHENYL)- 4- (4-MORPHOLIN -4¬YLMETHYL-PHENYL) - ISOXAZOLE-3-CARBOXYLlC ACID ETHYLAMIDE AND FORMULATIONS COMPRISING THESE FORMSInfo
- Publication number
- TN2009000357A1 TN2009000357A1 TNP2009000357A TN2009000357A TN2009000357A1 TN 2009000357 A1 TN2009000357 A1 TN 2009000357A1 TN P2009000357 A TNP2009000357 A TN P2009000357A TN 2009000357 A TN2009000357 A TN 2009000357A TN 2009000357 A1 TN2009000357 A1 TN 2009000357A1
- Authority
- TN
- Tunisia
- Prior art keywords
- phenyl
- polymorphs
- morpholin
- isoxazole
- ylmethyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000004677 hydrates Chemical class 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 2
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 title 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 2
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- NDAZATDQFDPQBD-UHFFFAOYSA-N luminespib Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 NDAZATDQFDPQBD-UHFFFAOYSA-N 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000011521 glass Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07103346 | 2007-03-01 | ||
| PCT/EP2008/052443 WO2008104595A1 (en) | 2007-03-01 | 2008-02-28 | Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2009000357A1 true TN2009000357A1 (en) | 2010-12-31 |
Family
ID=38134307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2009000357A TN2009000357A1 (en) | 2007-03-01 | 2009-08-28 | ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5¬(2,4-DIHYDROXY-5- ISOPROPYL-PHENYL)- 4- (4-MORPHOLIN -4¬YLMETHYL-PHENYL) - ISOXAZOLE-3-CARBOXYLlC ACID ETHYLAMIDE AND FORMULATIONS COMPRISING THESE FORMS |
Country Status (40)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200922595A (en) * | 2007-10-12 | 2009-06-01 | Novartis Ag | Organic compounds |
| TWI450898B (zh) * | 2008-07-04 | 2014-09-01 | Sigma Tau Res Switzerland Sa | 具有抗腫瘤活性之芳基異唑化合物 |
| WO2010060854A1 (en) | 2008-11-25 | 2010-06-03 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
| BR112012017994B8 (pt) * | 2010-01-21 | 2020-12-08 | Aprea Ab | composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio |
| JP2013519727A (ja) * | 2010-02-17 | 2013-05-30 | イルドン ファーム シーオー．，エルティーディー． | 新規の５員複素環誘導体及びその製造方法 |
| KR20120031854A (ko) | 2010-09-27 | 2012-04-04 | 한국전자통신연구원 | 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법 |
| WO2013015661A2 (en) * | 2011-07-28 | 2013-01-31 | Ildong Pharm Co.,Ltd. | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101166749B1 (ko) * | 2003-02-11 | 2012-07-27 | 베르날리스(캠브리지)리미티드 | 열쇼크 단백질 저해제로서의 이소옥사졸 화합물 |
| US20060070405A1 (en) * | 2004-10-06 | 2006-04-06 | Anheuser-Busch, Inc. | Method for the production of amber glass with reduced sulfur-containing emissions |
| CA2677651A1 (en) | 2007-02-15 | 2008-08-21 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| WO2010069458A1 (de) | 2008-12-17 | 2010-06-24 | Merck Patent Gmbh | Hexahalochromat(lll)-komplexe |
-
2008
- 2008-02-28 CN CN200880005490.7A patent/CN101636162A/zh active Pending
- 2008-02-28 WO PCT/EP2008/052443 patent/WO2008104595A1/en not_active Ceased
- 2008-02-28 KR KR1020097018126A patent/KR20090122218A/ko not_active Ceased
- 2008-02-28 ES ES08717228T patent/ES2384906T3/es active Active
- 2008-02-28 JP JP2009551218A patent/JP2010520176A/ja active Pending
- 2008-02-28 GE GEAP200811444A patent/GEP20115309B/en unknown
- 2008-02-28 AT AT08717228T patent/ATE552836T1/de active
- 2008-02-28 UA UAA200908592A patent/UA101950C2/ru unknown
- 2008-02-28 AR ARP080100831A patent/AR065519A1/es not_active Application Discontinuation
- 2008-02-28 DK DK08717228.4T patent/DK2131845T3/da active
- 2008-02-28 PT PT08717228T patent/PT2131845E/pt unknown
- 2008-02-28 AU AU2008220800A patent/AU2008220800B2/en not_active Ceased
- 2008-02-28 RS RS20120263A patent/RS52351B/sr unknown
- 2008-02-28 HR HRP20120535AT patent/HRP20120535T1/hr unknown
- 2008-02-28 UY UY30943A patent/UY30943A1/es not_active Application Discontinuation
- 2008-02-28 EP EP11192158.1A patent/EP2545921A3/en not_active Withdrawn
- 2008-02-28 EA EA200901141A patent/EA017075B1/ru not_active IP Right Cessation
- 2008-02-28 PL PL08717228T patent/PL2131845T3/pl unknown
- 2008-02-28 EP EP08717228A patent/EP2131845B1/en active Active
- 2008-02-28 CN CN201110226727.8A patent/CN102302500A/zh active Pending
- 2008-02-28 MX MX2009009233A patent/MX2009009233A/es active IP Right Grant
- 2008-02-28 SI SI200830688T patent/SI2131845T1/sl unknown
- 2008-02-28 NZ NZ578854A patent/NZ578854A/en not_active IP Right Cessation
- 2008-02-28 US US12/529,090 patent/US8163747B2/en active Active
- 2008-02-28 BR BRPI0807992-7A2A patent/BRPI0807992A2/pt not_active IP Right Cessation
- 2008-02-28 CA CA002678043A patent/CA2678043A1/en not_active Abandoned
- 2008-02-29 PE PE2008000418A patent/PE20090166A1/es not_active Application Discontinuation
- 2008-02-29 TW TW097107239A patent/TW200844102A/zh unknown
- 2008-02-29 CL CL200800618A patent/CL2008000618A1/es unknown
- 2008-02-29 PA PA20088771101A patent/PA8771101A1/es unknown
-
2009
- 2009-08-03 ZA ZA200905417A patent/ZA200905417B/xx unknown
- 2009-08-13 IL IL200401A patent/IL200401A0/en unknown
- 2009-08-21 CR CR10989A patent/CR10989A/es not_active Application Discontinuation
- 2009-08-28 TN TNP2009000357A patent/TN2009000357A1/fr unknown
- 2009-08-28 NI NI200900161A patent/NI200900161A/es unknown
- 2009-08-28 EC EC2009009602A patent/ECSP099602A/es unknown
- 2009-08-31 DO DO2009000209A patent/DOP2009000209A/es unknown
- 2009-08-31 MA MA32191A patent/MA31204B1/fr unknown
- 2009-08-31 GT GT200900236A patent/GT200900236A/es unknown
- 2009-09-01 CO CO09092694A patent/CO6210828A2/es not_active Application Discontinuation
- 2009-09-30 SM SM200900080T patent/SMAP200900080A/it unknown
-
2012
- 2012-03-08 US US13/415,268 patent/US8487095B2/en not_active Expired - Fee Related
- 2012-07-09 CY CY20121100610T patent/CY1113805T1/el unknown
-
2013
- 2013-07-10 US US13/938,659 patent/US20130296556A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000357A1 (en) | ACID ADDITION SALTS, HYDRATES AND POLYMORPHS OF 5¬(2,4-DIHYDROXY-5- ISOPROPYL-PHENYL)- 4- (4-MORPHOLIN -4¬YLMETHYL-PHENYL) - ISOXAZOLE-3-CARBOXYLlC ACID ETHYLAMIDE AND FORMULATIONS COMPRISING THESE FORMS | |
| EA201101308A1 (ru) | Применение ралфинамида для лечения биполярного расстройства | |
| NO20085068L (no) | Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| MY149731A (en) | Compounds | |
| NO20085066L (no) | 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| NO20085064L (no) | 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| MX383551B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida | |
| IL210577A (en) | Compound 1,2,3,4-tetrahydrocyclopenta [b] indole-3-yl acetic acid, salt, hydrate and solvent, pharmaceutical, compound, salt, hydrate, solvent or pharmaceutical for use as a medicine or treatment Salt, hydrate, solvent or pharmaceutical preparation in the manufacture of a drug and process for the preparation | |
| IL183415A0 (en) | Tartrate salt of isofagomine and methods of use | |
| NO20076695L (no) | Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser | |
| NZ582284A (en) | Carbamoyl-cyclohexanes for treating acute mania | |
| MX2010007426A (es) | Composiciones farmaceuticas para tratar trastorno del higado graso. | |
| TNSN08506A1 (en) | Substituted carboxamides | |
| UA88481C2 (ru) | Донепезила фумарат, пригодный для получения фармацевтических композиций | |
| MX2009002906A (es) | Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia. | |
| MY183153A (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl) -3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl) urea hydrochloride | |
| MX2009000762A (es) | 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central. | |
| UA94042C2 (ru) | Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса | |
| NZ593282A (en) | Ethanamine compounds and their use for treating depression | |
| NZ590041A (en) | Method of treating anxious major depressive disorder | |
| EA201100826A1 (ru) | Холиновые соли янтарной кислоты для лечения депрессий, страхов, шизофрении, нарушений сна и эпилепсии | |
| MX2014000870A (es) | Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina. | |
| UA98311C2 (ru) | Соединение 2-алкилиндазола для лечения определенных расстройств, связанных с цнс, способ его получения (варианты) и фармацевтическая композиция на его основе | |
| MXPA05013717A (es) | Derivados de acido 2-etoxi-2-fenilpropionico para el tratamiento de trastornos de lipido. | |
| TW200635575A (en) | Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome |